 - Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features with high risk for development of metastases, defined as prostate-specific antigen doubling time PSADT less than or equal to 10 months. PSADT is calculated using at least 3 prostate-specific antigen PSA values obtained during continuous ADT androgen deprivation therapy 